GT200900007A - Derivados de purina como agonistas de a2a - Google Patents

Derivados de purina como agonistas de a2a

Info

Publication number
GT200900007A
GT200900007A GT200900007A GT200900007A GT200900007A GT 200900007 A GT200900007 A GT 200900007A GT 200900007 A GT200900007 A GT 200900007A GT 200900007 A GT200900007 A GT 200900007A GT 200900007 A GT200900007 A GT 200900007A
Authority
GT
Guatemala
Prior art keywords
compounds
agonists
purine derivatives
adenosine
sales
Prior art date
Application number
GT200900007A
Other languages
English (en)
Inventor
Fairhurst Robin Alec
Taylor Roger John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900007A publication Critical patent/GT200900007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN TRATA DE COMPUESTOS DE FÓRMULA (I) O LOS ESTEREOISÓMEROS O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE W, R1, R2 Y R3 TIENEN LOS SIGNIFICADOS INDICADOS EN LA MEMORIA DESCRIPTIVA, SON ÚTILES PARA EL TRATAMIENTO DE LAS CONDICIONES MEDIADAS POR LA ACTIVACIÓN DEL RECEPTOR DE ADENOSINA A2A, EN ESPECIAL LAS ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VÍAS RESPIRATORIAS. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS, Y UN PROCESO PARA LA PREPARACIÓN DE LOS COMPUESTOS.
GT200900007A 2006-07-13 2009-01-12 Derivados de purina como agonistas de a2a GT200900007A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06117168A EP1889846A1 (en) 2006-07-13 2006-07-13 Purine derivatives as A2a agonists

Publications (1)

Publication Number Publication Date
GT200900007A true GT200900007A (es) 2009-11-30

Family

ID=37496423

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900007A GT200900007A (es) 2006-07-13 2009-01-12 Derivados de purina como agonistas de a2a

Country Status (20)

Country Link
US (1) US8071565B2 (es)
EP (2) EP1889846A1 (es)
JP (1) JP2009542753A (es)
KR (1) KR20090016017A (es)
CN (1) CN101479267B (es)
AU (1) AU2007271944A1 (es)
BR (1) BRPI0714216A2 (es)
CA (1) CA2656012A1 (es)
CR (1) CR10520A (es)
EC (1) ECSP099063A (es)
ES (1) ES2393931T3 (es)
GT (1) GT200900007A (es)
IL (1) IL196330A0 (es)
MA (1) MA30693B1 (es)
MX (1) MX2009000375A (es)
NO (1) NO20090664L (es)
RU (1) RU2009104764A (es)
TN (1) TNSN08544A1 (es)
WO (1) WO2008006563A1 (es)
ZA (1) ZA200810671B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
WO2008055874A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
WO2009050199A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
CA2736229C (en) * 2008-09-05 2015-06-09 Acucela Inc. Sulfur-linked compounds for treating opthalmic diseases and disorders
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN117069627B (zh) * 2022-10-13 2025-08-26 上海康斯维克生物医药有限公司 4-(3-(3-氨磺酰基苯基)脲基)丁酸化合物、其荧光标记物、制备方法及用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) 1986-07-10 1989-10-10 Board Of Governors Of Wayne State University Process for the preparation of cyclopentanoids and novel intermediates produced thereby
US4954504A (en) 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
EP0267878A1 (en) 1986-11-14 1988-05-18 Ciba-Geigy Ag N9-cyclopentyl-substituted adenine derivatives
JP2586897B2 (ja) 1987-03-09 1997-03-05 富士薬品工業株式会社 光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
SG80526A1 (en) 1990-09-25 2001-05-22 Rhone Poulenc Rorer Int Compounds having antihypertensive and anti- ischemic properies
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
EA000884B1 (ru) 1996-01-02 2000-06-26 Рон-Пуленк Рорер Фармасьютикалз Инк. Способ получения 2,4-дигидроксипиридина и 2,4-дигидрокси-3-нитропиридина
US6376472B1 (en) 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6211165B1 (en) 1997-05-09 2001-04-03 The Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CN1313861A (zh) * 1998-06-23 2001-09-19 葛兰素集团有限公司 2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU5879299A (en) 1998-10-16 2000-05-08 Monaghan, Sandra Marina Adenine derivatives
PT1140933E (pt) 1998-12-31 2004-12-31 Aventis Pharma Inc Processo para preparar derivados n6-substituidos de desaza-adenosina
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
CN1259056C (zh) 2001-01-16 2006-06-14 坎-菲特生物药物有限公司 腺苷a3受体激动剂用于抑制病毒复制的用途
GB2372741A (en) 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
NZ532062A (en) 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1496911B1 (en) 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases
PL1699459T3 (pl) 2003-12-29 2007-12-31 Can Fite Biopharma Ltd Sposób leczenia stwardnienia rozsianego
AU2005218997B2 (en) 2004-03-05 2012-05-10 Cbt Development Limited Adenosine receptor agonists
US7396825B2 (en) 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
ES2432113T3 (es) 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
AU2006210422B2 (en) 2005-02-04 2012-09-13 Takeda Pharmaceutical Company Limited Inhibitors of E1 activating enzymes
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1959939B1 (en) 2005-11-30 2012-01-11 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
JP5414277B2 (ja) 2006-01-26 2014-02-12 ザ・ガバメント・オブ・ジ・ユナイテッド・ステイツ・オブ・アメリカ・レプリゼンテッド・バイ・ザ・セクレタリー・ディパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ Ａ３アデノシンレセプタ・アロステリックモジュレータ
CN106008512B (zh) 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
US20080027022A1 (en) 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
GB0607944D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PE20080361A1 (es) * 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
WO2008055874A1 (en) 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
US20080312160A1 (en) 2007-04-09 2008-12-18 Guerrant Richard L Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
WO2009006046A1 (en) 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
WO2009050199A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
US20090181934A1 (en) 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
US8183225B2 (en) 2007-11-08 2012-05-22 New York University Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
CN101938904A (zh) 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛

Also Published As

Publication number Publication date
AU2007271944A1 (en) 2008-01-17
CN101479267A (zh) 2009-07-08
KR20090016017A (ko) 2009-02-12
EP2044070B1 (en) 2012-08-22
EP2044070A1 (en) 2009-04-08
US8071565B2 (en) 2011-12-06
MX2009000375A (es) 2009-01-27
WO2008006563A1 (en) 2008-01-17
ZA200810671B (en) 2009-11-25
EP1889846A1 (en) 2008-02-20
US20100240680A1 (en) 2010-09-23
CR10520A (es) 2009-03-19
TNSN08544A1 (en) 2010-04-14
MA30693B1 (fr) 2009-09-01
BRPI0714216A2 (pt) 2013-01-29
NO20090664L (no) 2009-02-11
IL196330A0 (en) 2009-09-22
CA2656012A1 (en) 2008-01-17
ECSP099063A (es) 2009-02-27
JP2009542753A (ja) 2009-12-03
CN101479267B (zh) 2012-05-02
RU2009104764A (ru) 2010-08-20
ES2393931T3 (es) 2013-01-02

Similar Documents

Publication Publication Date Title
GT200900007A (es) Derivados de purina como agonistas de a2a
CR10621A (es) Derivados de adenosina como agonistas del receptor a2a
GT200800219A (es) Derivados de purina para utilizarse como agonistas del receptor de adenosina a2a
ECSP077404A (es) Derivados de purina para usarse como agonistas de receptores a-2a de adenosina
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
NI201300107A (es) Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
PA8825301A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
GT200600013A (es) Compuestos organicos
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NO20085257L (no) Purinonderivater som HM74a-agonister
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
NO20085099L (no) Puritonderivativer som HM74A agonister
UY30282A1 (es) Compuestos quimicos
BRPI0515030A (pt) derivados de purina como agonistas de receptor de adenosina a3 e a1
MX376743B (es) Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos
HN2008001666A (es) Derivados acidos de cicloalquilamino